Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis
June 26, 2020 03:00 ET
|
Highlight Therapeutics
MADRID, Spain, June 26, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the dosing...
Highlight Therapeutics appoints Dr. Carlos Paya as Executive Chairman and Significantly expands Scientific Advisory Board
April 17, 2020 04:01 ET
|
Highlight Therapeutics
Dr Ralph Weichselbaum, Dr. Antoni Ribas & Michael Docherty appointed to SAB Company renamed to Highlight Therapeutics MADRID, Spain, April 17, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics...
Highlight Therapeutics announces name change from Bioncotech and launch of new website
April 17, 2020 04:00 ET
|
Highlight Therapeutics
MADRID, Spain, April 17, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces that it has changed its...
Bioncotech Therapeutics Phase I BO-112 Data Presented at ESMO Immuno-Oncology Congress 2019
December 12, 2019 04:00 ET
|
Bioncotech Therapeutics
MADRID, Spain, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Bioncotech Therapeutics ("Bioncotech"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the...
Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration with MSD
December 10, 2019 04:00 ET
|
Bioncotech Ltd
MADRID, Spain, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Bioncotech Therapeutics ("Bioncotech"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces it has...